Biorevert
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Biorevert uses network‑control systems biology to develop non‑lethal therapies that revert cancer and aging cells to healthy states.
OncologyAging
Technology Platform
The MObyDiCK platform applies systems‑biology and network‑control theory to identify master regulator genes whose modulation can revert disease phenotypes, enabling rapid target discovery and novel drug design.
Opportunities
Successful pre‑clinical proof‑of‑concept could unlock licensing of the MObyDiCK platform and attract partnership deals for oncology and age‑related indications.
Risk Factors
Scientific uncertainty around network‑level reversion and lack of regulatory precedent pose significant development and approval risks.
Competitive Landscape
Few companies pursue non‑lethal reversion strategies; Biorevert differentiates through its systems‑biology platform and network‑control approach, but must demonstrate translational efficacy against established cytotoxic and senolytic therapies.